The Life Sciences Industry Insights
The Life Sciences Industry Insights Newsletter
Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on PharmaXcelerate as their must-read source for the latest news, analysis and data on drugs and the companies that make them.
Every business day, PharmaXcelerate and its family of publications covers the waterfront in the pharma business, from late-stage drug development through the entire lifecycle. Learn about regulatory approvals, payer negotiations, manufacturing, marketing, patent fights, government investigations and regulations, M&A and beyond.
A distinctive element of our summits is the active participation of local pharmaceutical authorities and regulatory agencies, offering insight into national priorities, evolving standards, and regional market dynamics.
All Categories

The Future of Sterile Fill-Finish: How Advanced Manufacturing Is Redefining Injectable Production
The future of sterile fill-finish is becoming faster, smarter and more automated. Jubilant Pharmova’s latest FDA-cleared isolator-based manufacturing line in Spokane highlights how advanced technology is helping the industry expand injectable production while strengthening sterility assurance, flexibility and quality.

Roche and Eli Lilly Advance Alzheimer’s Diagnosis With FDA-Cleared pTau217 Blood Test
A simple blood test could change how Alzheimer’s disease is detected and assessed. Roche and Eli Lilly’s newly FDA-cleared pTau217 test brings blood-based biomarker testing one step closer to routine clinical care, potentially making Alzheimer’s assessment more accessible, scalable and less invasive.

Replimune wins FDA approval for Tudriqev in advanced melanoma after two previous rejections

Commercial Readiness Starts Earlier Than You Think: Why Manufacturing Strategy Can Make or Break a Product Launch

Blueprints for the Future: How AI Is Transforming Pharmaceutical Facility Design

Sustainability vs. Sterility: Can Single-Use Technologies Become Greener?

Annex 1 One Year Later: What Pharmaceutical Manufacturers Have Learned

Validation 4.0: Why Pharmaceutical Validation Is Moving Beyond Documentation

AI in GxP Manufacturing: How to Validate AI Without Breaking Compliance

FDA Pauses "Radical Transparency" Initiative After Industry Pushback Over Drug Rejection Letters
"How much transparency is too much when it comes to protecting innovation?"

FDA Expands Sunscreen Options for the First Time in 20 Years
Sandeep Murali - Director of Data Excellence - Mundipharma Medical Company Ltd - MDM LS- Berlin 2025
Event Highlights - 11th Annual Master Data and Data Governance Excellence in Life Sciences - Berlin
5th Annual Cleanroom Design & Engineering Forum - Event Highlights

Hemophilia in Focus: A Wake-Up Call for Pharma Innovation

Total Investment of Approx. USD 8.5 Million in Malaria and NTD R&D Projects With Partners Including MMV, GSK, Tanabe Pharma, Eisai and DNDi

AstraZeneca Expands Breztri’s Reach With FDA Approval for Asthma

Why the Food Allergy Market Has Big Pharma Going Nuts Again

Engineering the Future of Biopharma: A Conversation with Kim Gauthier on Innovation, Sustainability and Next-Generation Manufacturing
"What I’ve learned designing and operating facilities across different manufacturing environments is that there is no one-size-fits-all solution. Each modality brings its own unique technical, regulatory, and operational challenges that need to be considered early in the design."

Leadership Perspectives with Edita and Aaron
“The industry is actively transforming manufacturing through connected PAT ecosystems - where AI, digital twins, and predictive analytics are enabling real-time process understanding and improved product quality.”

Waiting for Perfect Certainty May Be the Biggest Risk Facing Pharma Today - An interview with Gisèle Fahmi, Director, Internal Manufacturing Operations Quality (IMOQ) QC Digitization, Pfizer
Artificial intelligence is no longer a future conversation for life sciences. In this exclusive PharmaXcelerate USA 2026 interview, Gisèle Fahmi explores how organizations can accelerate AI adoption, modernize compliance, build trusted data ecosystems and prepare their workforce for the next era of pharmaceutical manufacturing and quality operations.